Skip to main content
. 2024 Jun 24;15(6):446. doi: 10.1038/s41419-024-06844-x

Fig. 2. VHL decreases UBE3B protein levels in breast cancer cells.

Fig. 2

A Protein levels of endogenous UBE3B were assessed in MDA-MB-231 and T47D cells stably expressing either wild-type (WT) or catalytically inactive (Y112H) Flag-VHL. B Protein levels of endogenous UBE3B in control or VHL-knockdown (VHL-KD) MDA-MB-231 and T47D cells. C–F The half-life of UBE3B protein in MDA-MB-231 (C, D) or T47D (E, F) cells expressing Flag-VHL. Cells were treated with 10 μg/mL CHX for the indicated time (mean ± SD, n = 3). ****P < 0.0001, by 2-way ANOVA Tukey’s multiple comparisons test. G–J The half-life of UBE3B protein was analyzed in scrambled shRNA (SC) or VHL-KD MDA-MB-231 (G, H) or T47D (I, J) cells. Cells were treated with 10 μg/mL CHX for the indicated time (mean ± SD, n = 3). ****P < 0.0001, by 2-way ANOVA Tukey’s multiple comparisons test. K, L UBE3B protein levels in Flag-VHL-expressing MDA-MB-231 (K) and T47D (L) cells with or without MG132 treatment. EV, empty vector.